<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>佰傲谷BioValley | wechat-feeds</title><link>http://MzU1NTg4OTM3Mg.favicon.privacyhide.com/favicon.ico</link><description>佰傲谷致力于打造一个垂直于生物制品领域的第三方平台。为生物制药企业提供品牌推广、技术咨询、项目交易、企业合作、人才培养等服务。为生物制药行业从业人员提供沟通交流、会议培训、工作求职、个人展示平台。</description><managingEditor> (hellodword)</managingEditor><pubDate>Sat, 13 Mar 2021 12:11:49 +0800</pubDate><image><url>http://MzU1NTg4OTM3Mg.favicon.privacyhide.com/favicon.ico</url><title>佰傲谷BioValley | wechat-feeds</title><link>http://MzU1NTg4OTM3Mg.favicon.privacyhide.com/favicon.ico</link><width>64</width><height>64</height></image><item><title>1000KDa超大抗VEGF药SI-301国内临床申报获受理</title><link>https://mp.weixin.qq.com/s/5zO3uA3sR3mBKYzjYjEF3w</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/qygMQht6xpYH4xDV8HADQPrbqicT1bV9mPNe1Vcltzyn5CM4Q4PIVVko5Yjrk0DZpkibaaLX4BC9tGotAUiaJFn6Q/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>]]></content:encoded><pubDate>Sat, 13 Mar 2021 10:56:41 +0800</pubDate></item><item><title>中国免疫治疗大事记【细胞治疗·基因治疗篇】</title><link>https://mp.weixin.qq.com/s/rHlwVq7UjX20Iub-q8FCYQ</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/qygMQht6xpZtnhmCDYnZrxU531ib2Ey5RkGiciaWk2ZPY0cvRs7q9fO220cT2N7eOq7aWia3aYybnw45nTibYOpkH2g/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>谁将拔得头筹？]]></content:encoded><pubDate>Sat, 13 Mar 2021 10:56:41 +0800</pubDate></item><item><title>继港股之后，诺诚健华拟科创板上市</title><link>https://mp.weixin.qq.com/s/CSQKjIFfIJPiQKKc6eYVGA</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/qygMQht6xpZtnhmCDYnZrxU531ib2Ey5R6Q9vRS7zLmJuicVsbtaQGvOvWTa1vRpTrSo3sViaSyPicaagnOY8MjicVg/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>]]></content:encoded><pubDate>Fri, 12 Mar 2021 12:29:36 +0800</pubDate></item><item><title>永泰生物宣布CAR-T产品恢复一期临床，早前投资30亿建设生产基地</title><link>https://mp.weixin.qq.com/s/tzf0JbDWYnoccn1-oqOAPA</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/qygMQht6xpZtnhmCDYnZrxU531ib2Ey5Rx443Uz62Oic9ShiaJ8a5jmpBe2l0qWXxV1fqibLQfzUUbYP9bWISsVnMg/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>细胞治疗又一选手下场。]]></content:encoded><pubDate>Fri, 12 Mar 2021 12:29:36 +0800</pubDate></item><item><title>基因泰克的Actemra在COVID-19试验中未能达到其主要终点</title><link>https://mp.weixin.qq.com/s/XD7Yor0v6zHafT1FPmNuuA</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/qygMQht6xpZtnhmCDYnZrxU531ib2Ey5Rx443Uz62Oic9ShiaJ8a5jmpBe2l0qWXxV1fqibLQfzUUbYP9bWISsVnMg/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>▲TG-Bio携手600余位行业同仁，4月即将开幕▲罗氏(Roche)旗下基因泰克(Genentech)近日]]></content:encoded><pubDate>Fri, 12 Mar 2021 12:29:36 +0800</pubDate></item><item><title>南非主要变异株总体保护效力48.6%，Novavax公布其新冠疫苗完整分析</title><link>https://mp.weixin.qq.com/s/gFqXsGFULWI7xV0Q3bHEjA</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/qygMQht6xpZtnhmCDYnZrxU531ib2Ey5RTcCJ6BgxZZrtZyrsovhB3N7teFdAQ4GicZVtLicSP8od6LJiaDwA8UbAg/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>]]></content:encoded><pubDate>Fri, 12 Mar 2021 12:29:36 +0800</pubDate></item><item><title>【免费参会限时开放】QbD第二届生物药质量科学大会！</title><link>https://mp.weixin.qq.com/s/YtSwlbFCCVTie5Eg-u137g</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/qygMQht6xpZtnhmCDYnZrxU531ib2Ey5RmEfcRibak0qG3NfrdmWI0nP1dia9lWwWF7Zxic59ENxO9aLTSyzzCLu6g/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>文附最新大会议程！]]></content:encoded><pubDate>Fri, 12 Mar 2021 12:29:36 +0800</pubDate></item><item><title>2021年面临专利悬崖的Top3药物，罗氏首当其冲、艾伯维紧随其后</title><link>https://mp.weixin.qq.com/s/SkP4jhT8u5dXeR7x8willQ</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/qygMQht6xpbm30uKfdw4SRyjibPccFDib9qC2x1iauicjFRgabt6tNiagNFS0Foib6QhN2mgLeWTTdcfz45Swc2kop6g/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>罗氏(Roche、艾伯维(AbbVie)和辉瑞(Pfizer)等多款药物将失去在美国市场的专利权。]]></content:encoded><pubDate>Thu, 11 Mar 2021 12:53:13 +0800</pubDate></item><item><title>赛分科技完成C轮融资，引进重量级战略投资人</title><link>https://mp.weixin.qq.com/s/cFK2QZx3Jg1zBcuYQdstlQ</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/qygMQht6xpbm30uKfdw4SRyjibPccFDib9DQCsKvsDtKepucx3spJjuyjKNwBZokgNy1NSwtTz1RlVrPadb1hictQ/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>夯实生物大分子色谱分离技术领域的领导者地位]]></content:encoded><pubDate>Thu, 11 Mar 2021 12:53:13 +0800</pubDate></item><item><title>石药集团1.7亿元引进康诺亚IL-4R抗体</title><link>https://mp.weixin.qq.com/s/NDtchlzlqjtnXH0hhL0I_w</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/qygMQht6xpbm30uKfdw4SRyjibPccFDib9JFmtoAsxevG0kkl60hc4SYVGulkLeKTodtqBvhO5gpGColDB6KMewg/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>]]></content:encoded><pubDate>Thu, 11 Mar 2021 12:53:13 +0800</pubDate></item><item><title>潜力比肩PD-1的靶点，百济神州有望拿到first-in-class：HPK1抑制剂获批1期临床试验</title><link>https://mp.weixin.qq.com/s/X0ZG2Fxgnu4SM--T85QMSQ</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/qygMQht6xpbm30uKfdw4SRyjibPccFDib92X8xtWjf5yIYwQRWgKgNy951Nia4orTN6hTkOo5lMdENJfH6I4XqheQ/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>百济神州宣布启动一项针对HPK1抑制剂BGB-15025的1期临床试验。]]></content:encoded><pubDate>Thu, 11 Mar 2021 12:53:13 +0800</pubDate></item><item><title>赛分科技 诚聘人才</title><link>https://mp.weixin.qq.com/s/RN0SzD4qdXnELOh0q0kXzw</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/qygMQht6xpbm30uKfdw4SRyjibPccFDib97h41lfrQUZrdfQTr66fXcfRlcTbIiadBoYewOQshVh0Z1zW8YqpkcaQ/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>赛分科技 诚聘人才]]></content:encoded><pubDate>Thu, 11 Mar 2021 12:53:13 +0800</pubDate></item><item><title>灵活优势凸显，mRNA疫苗快速转向针对新冠突变毒株</title><link>https://mp.weixin.qq.com/s/Cl1iKZClSlM1tdmTfc7wxQ</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/qygMQht6xpaTREuBgbUfE8IwcqrDjymhnXjyBTHdLdCXvXsBCZnmxkvwZFoibLNxCoozS4RVnopThhtXNhzwZFQ/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>]]></content:encoded><pubDate>Wed, 10 Mar 2021 17:01:33 +0800</pubDate></item><item><title>CD19靶向药物开发百花齐放，恺佧生物推出新一代高活性定点荧光标记CD19蛋白</title><link>https://mp.weixin.qq.com/s/Ygu79uOn6xiu9dLXzOTrMw</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/bK2EFoTdFIsib0wcEMAsyUDedFzoplibhZVTBJicQIGzlnuYick9EhtFl1k2AqwBibnbJqGWc2GQQ6MLzaicnVPbfhZg/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>闪闪发光的CD19靶点]]></content:encoded><pubDate>Wed, 10 Mar 2021 17:01:33 +0800</pubDate></item><item><title>股价大涨8%！拟A股IPO!好消息不断的荣昌生物 1 类新药「泰它西普」正式获 NMPA 批准</title><link>https://mp.weixin.qq.com/s/9RjxzJblZe1h7XgSfBi1MA</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/qygMQht6xpaTREuBgbUfE8IwcqrDjymhyn1gYutvmMeckSrHnKnS9bzL0SG9iaWAicfNvibxckm8vZjicic1UIposZg/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>Insight数据库]]></content:encoded><pubDate>Wed, 10 Mar 2021 17:01:33 +0800</pubDate></item><item><title>【免费注册限时开启】2021年首场生物药分析研发&amp;质量控制论坛！</title><link>https://mp.weixin.qq.com/s/tzQLVFPkk4lPGDT5FXs1Vg</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/qygMQht6xpaTREuBgbUfE8IwcqrDjymhSe1l7Hy1NLtjJibTeZuhiaKEVU8DLicfzos0EibZic1Ip7qOicyvneQqicyOw/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>如果生物制药有蝴蝶效应，那质量就是轻扇的翅膀]]></content:encoded><pubDate>Wed, 10 Mar 2021 17:01:33 +0800</pubDate></item><item><title>总能得到相同结果，几乎无需优化，这就是重组兔单抗！</title><link>https://mp.weixin.qq.com/s/UkRMgjU2lIY3M3aV-DTbSA</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/qygMQht6xpZB2ia4icXiaQsvGVIygstU0nGibMVB7hgJXP9pgsS63SgU6wMAAMdgPrc0uYmZ7OTAH8WSsHxH1cp4XA/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>这么优秀的重组兔单抗，你知道么？]]></content:encoded><pubDate>Tue, 09 Mar 2021 11:52:42 +0800</pubDate></item><item><title>【佰家言】荣昌生物姚雪静：质量，是药与人之间的“守夜人”</title><link>https://mp.weixin.qq.com/s/hsyvV6nhDYAUdvs6irKfMg</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/qygMQht6xpZxcf2GxgFWgUqUNIh1rSiaCUHldWZFWdZMEmmicg3oW6C5LzLn9TNPpTMk6qV24sa2fG4mUgt2ib4AQ/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>接受质量问题的存在必然性，思考它、并尝试去解决它]]></content:encoded><pubDate>Tue, 09 Mar 2021 11:52:42 +0800</pubDate></item><item><title>对线礼来-嘉和生物宣布GB491获得一线及二线晚期乳腺癌临床试验及伦理四项批准</title><link>https://mp.weixin.qq.com/s/FWQSMpbGcRsbfg9KPXXufA</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/qygMQht6xpZxcf2GxgFWgUqUNIh1rSiaC0AFoAniayNMYu9h9icM2Pj8lFFs3V0SoaRQhWZViawkEicH2kHANn1gz2g/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>佰傲谷分享]]></content:encoded><pubDate>Tue, 09 Mar 2021 11:52:42 +0800</pubDate></item><item><title>最新嘉宾阵容！QbD第二届生物药质量科学大会早鸟注册火爆进行中！</title><link>https://mp.weixin.qq.com/s/5luiiPfV6ZcLs0TzfQO_3w</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/qygMQht6xpZxcf2GxgFWgUqUNIh1rSiaCUibZUvAQ2UCAusmE8jxZZJEW0L7lJqI4Oia7ia6icN9g1FAOuzUibYwLFZg/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>将“质量·科学”进行到底！300+门票已被抢光，早鸟优惠限时放送中！]]></content:encoded><pubDate>Tue, 09 Mar 2021 11:52:42 +0800</pubDate></item></channel></rss>